AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11919241 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (30 units over 24 hours on day 1) followed by cisplatin (50 mg/m²), ifosfamide (5 g/m² over 24 hours), and mesna (6 g/m² during ifosfamide infusion and the following 12 hours)
Number of subjects: 303
Study 10361863 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d)
Number of subjects: 22
Study 10361863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8522468 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 30 mg
Number of subjects: 0
Study 8522468 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 mg
Number of subjects: 0
Study 8522468 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 300 mg
Number of subjects: 0
Study 8522468 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 600 mg
Number of subjects: 0
Study 8522468 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 1000 mg
Number of subjects: 0
Study 8522468 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin (all doses)
Number of subjects: 0
Study 2022159 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ranitidine (0.2 mg/kg/hr)
Number of subjects: 0
Study 2022159 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of ranitidine (50 mg every 4 hr)
Number of subjects: 0
Study 7017068 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)‐isomer of tranylcypromine (TCP)
Number of subjects: 20
Study 7017068 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)‐isomer of tranylcypromine (TCP)
Number of subjects: 20
Study 31607719 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone treatment
Number of subjects: 130
Study 31607719 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 130
Study 27825977 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus testing arm (n=100) with repeated human papillomavirus testing, cytologies, and colposcopies if persistently human papillomavirus-positive.
Number of subjects: 195
Study 27825977 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=95) with random colposcopies and tests.
Number of subjects: 195
Study 27825977 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown persistence status (women who had human papillomavirus persistence but did not continue with repeated tests).
Number of subjects: 195
Study 26293575 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 320/9 μg (twice daily)
Number of subjects: 810
Study 26293575 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 9 μg (twice daily)
Number of subjects: 810
Study 26293575 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliever salbutamol 90 μg
Number of subjects: 810
Study 26293575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean reliever use over 1 week
Number of subjects: 810
Study 24066178 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised feedback about physical activity (simple, visual, or contextualised)
Number of subjects: 466
Study 21893941 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose GH therapy (0.033 mg/kg/day) for 2 years
Number of subjects: 149
Study 21893941 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose GH therapy (0.100 mg/kg/day) for 1 year
Number of subjects: 149
Study 21893941 — intervention group
Group type: EXPERIMENTAL
Intervention: mid-dose GH therapy (0.067 mg/kg/day) for 1 year
Number of subjects: 149
Study 21893941 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (all doses)
Number of subjects: 149
Study 19682793 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid blockade)
Number of subjects: 160
Study 19682793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 17185207 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling + Contingency contracting (PC + CC)
Number of subjects: 794
Study 17185207 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 794
Study 17185207 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling (PC)
Number of subjects: 794
Study 17185207 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency contracting (CC)
Number of subjects: 794
Study 15145300 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on melatonin (MEL)
Number of subjects: 31
Study 15145300 — intervention group
Group type: COMPARATOR
Intervention: Add-on placebo (P)
Number of subjects: 31
Study 11441213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Adjustment to Stroke Scale (self-rated attitude scale)
Number of subjects: 372
Study 11441213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood assessments (Hospital Anxiety and Depression Scale, General Health Questionnaire 30)
Number of subjects: 372
Study 9836525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal hypoglycemia (48 +/- 2 mg/dl)
Number of subjects: 15
Study 9836525 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal euglycemia (109 +/- 1 mg/dl)
Number of subjects: 15
Study 8020526 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 350 mgI/ml
Number of subjects: 100
Study 8020526 — intervention group
Group type: COMPARATOR
Intervention: iopromide 370 mgI/ml
Number of subjects: 100
Study 2246716 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention to reduce energy-dense foods and rely on child's appetite control
Number of subjects: 100
Study 2246716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study 2246716 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 100
Study 2246716 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 7435247 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hydralazine q.i.d.
Number of subjects: 20
Study 7435247 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hydralazine b.i.d.
Number of subjects: 20
Study 7435247 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release hydralazine b.i.d.
Number of subjects: 20
Study 31929980 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg/day
Number of subjects: 1
Study 31929980 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg/bid
Number of subjects: 1
Study 31929980 — intervention group
Group type: COMPARATOR
Intervention: Control (standard dosage of esomeprazole)
Number of subjects: 1
Study 27681944 — intervention group
Group type: EXPERIMENTAL
Intervention: dalotuzumab 10 mg/kg once weekly (arm A)
Number of subjects: 69
Study 27681944 — intervention group
Group type: EXPERIMENTAL
Intervention: dalotuzumab 7.5 mg/kg every second week (arm B)
Number of subjects: 69
Study 27681944 — intervention group
Group type: COMPARATOR
Intervention: placebo (arm C)
Number of subjects: 69
Study 24933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm of the study (screened for complications)
Number of subjects: 599
Study 23543346 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 25
Study 23543346 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 25
Study 23543346 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen and Fentanyl
Number of subjects: 25
Study 21816977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (IT)
Number of subjects: 1533
Study 21816977 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 1533
Study 19508464 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 1013
Study 19508464 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg
Number of subjects: 1013
Study 19508464 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 mg/day
Number of subjects: 1013
Study 19508464 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 20 mg/day
Number of subjects: 1013
Study 19508464 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 40 mg/day
Number of subjects: 1013
Study 18056233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 1151
Study 18056233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation with adjunctive psychiatric rehabilitation
Number of subjects: 1151
Study 15384877 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed preterm formula
Number of subjects: 122
Study 15384877 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed preterm formula
Number of subjects: 122
Study 15384877 — intervention group
Group type: COMPARATOR
Intervention: Standard preterm formula
Number of subjects: 122
Study 11846130 — intervention group
Group type: COMPARATOR
Intervention: Filtered products
Number of subjects: 431
Study 11846130 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-filtered products
Number of subjects: 431
Study 9740915 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically-guided cultures from chronic sinusitis patients
Number of subjects: 265
Study 9740915 — intervention group
Group type: COMPARATOR
Intervention: Topical nasal steroids
Number of subjects: 265
Study 9740915 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy volunteers
Number of subjects: 265
Study 8049498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulofenur (LY186641) given orally daily x 21 schedule
Number of subjects: 32
Study 8049498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulofenur (LY186641) given orally daily x 5 for 3 weeks schedule
Number of subjects: 32
Study 2924255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive maintenance therapy with 6-mercaptopurine and methotrexate, plus vincristine and prednisone pulses (treatment 1)
Number of subjects: 434
Study 2924255 — intervention group
Group type: COMPARATOR
Intervention: Less intensive maintenance therapy with 6-mercaptopurine and methotrexate, plus vincristine and prednisone pulses (treatment 2)
Number of subjects: 434
Study 2924255 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 434
Study 985067 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective myocardial hypothermic arrest (15 to 18 C) with coolant perfusion (7 to 10 C)
Number of subjects: 0
Study 985067 — intervention group
Group type: COMPARATOR
Intervention: Ventricular fibrillation and moderate hypothermia
Number of subjects: 0
Study 31290761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual activity and functioning in postmenopausal women
Number of subjects: 4418
Study 31290761 — intervention group
Group type: COMPARATOR
Intervention: Partner's medical condition or sexual dysfunction
Number of subjects: 4418
Study 31290761 — intervention group
Group type: COMPARATOR
Intervention: Own physical health or menopause-related symptoms
Number of subjects: 4418
Study 31290761 — intervention group
Group type: COMPARATOR
Intervention: Low libido
Number of subjects: 4418
Study 31290761 — intervention group
Group type: COMPARATOR
Intervention: Relationship problems
Number of subjects: 4418
Study 31290761 — intervention group
Group type: COMPARATOR
Intervention: Logistics and perceptions of ageing
Number of subjects: 4418
Study 31290761 — intervention group
Group type: COMPARATOR
Intervention: Positive sexual experiences
Number of subjects: 4418
Study 31290761 — intervention group
Group type: COMPARATOR
Intervention: Seeking medical help for sexual problems
Number of subjects: 4418
Study 28715503 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin continuation (100 mg/day until operative day)
Number of subjects: 48
Study 28715503 — intervention group
Group type: COMPARATOR
Intervention: Aspirin discontinuation (4 days before the operative day)
Number of subjects: 48
Study 28715503 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin continuation
Number of subjects: 48
Study 28715503 — intervention group
Group type: COMPARATOR
Intervention: Aspirin discontinuation
Number of subjects: 48
Study 26168823 — intervention group
Group type: COMPARATOR
Intervention: Propofol for anesthetic maintenance (Group A)
Number of subjects: 122
Study 26168823 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sevoflurane (0.8% end-tidal) with propofol (Group B)
Number of subjects: 122
Study 26168823 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 122
Study 23883691 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic sports drink (osmolality 317 mOsm/kg)
Number of subjects: 6
Study 23883691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic sports drink (osmolality 193 mOsm/kg)
Number of subjects: 6
Study 23883691 — intervention group
Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 6
Study 21725231 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 39
Study 21725231 — intervention group
Group type: COMPARATOR
Intervention: Open Nissen fundoplication
Number of subjects: 39
Study 19372325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 44
Study 19372325 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 44
Study 19372325 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 44
Study 19372325 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 44
Study 16443448 — intervention group
Group type: EXPERIMENTAL
Intervention: Principled connections
Number of subjects: 0
Study 15067027 — intervention group
Group type: EXPERIMENTAL
Intervention: S plus CT (Surgery plus Chemotherapy)
Number of subjects: 3791
Study 15067027 — intervention group
Group type: EXPERIMENTAL
Intervention: S plus RT plus CT (Surgery plus Radiotherapy plus Chemotherapy)
Number of subjects: 3791
Study 11744592 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliCath(TM) catheter
Number of subjects: 19
Study 11744592 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiQ(TM) catheter
Number of subjects: 19
Study 11744592 — intervention group
Group type: COMPARATOR
Intervention: Conventional bolus thermodilution
Number of subjects: 19
Study 9304439 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% WP-934 ophthalmic solution
Number of subjects: 29
Study 9304439 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% WP-934 ophthalmic solution
Number of subjects: 29
Study 7686715 — intervention group
Group type: COMPARATOR
Intervention: Intravenous piperacillin (PIPC) 2 g once after surgery, and twice on the following day (Group A)
Number of subjects: 104
Study 7686715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous piperacillin (PIPC) followed by oral tosufloxacin tosilate (TFLX) 300 mg twice daily from the second to the fifth day (Group B)
Number of subjects: 104
Study 3795301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (1.0 gm IV q 6 h) starting before tube thoracostomy and terminating 12 hours after removal
Number of subjects: 58
Study 3795301 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic therapy
Number of subjects: 58
Study 31066988 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexanide
Number of subjects: 88
Study 31066988 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 88
Study 28605224 — intervention group
Group type: EXPERIMENTAL
Intervention: HEK (phase change heat emergency kit)
Number of subjects: 26
Study 28605224 — intervention group
Group type: COMPARATOR
Intervention: CON (control, without HEK)
Number of subjects: 26
Study 26855430 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cuff deflation and insertion of an in‐line speaking valve during mechanical ventilation
Number of subjects: 30
Study 26855430 — intervention group
Group type: COMPARATOR
Intervention: Standard cuff deflation and a speaking valve during self‐ventilation
Number of subjects: 30
Study 25267335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve blocks with ropivacaine
Number of subjects: 60
Study 25267335 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided nerve blocks with saline (control)
Number of subjects: 60
Study 22805598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (SMS and mobile phone voucher component)
Number of subjects: 2550
Study 22805598 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 2550
Study 22805598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (specifically for urban women)
Number of subjects: 2550
Study 22805598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (rural women)
Number of subjects: 2550
Study 20863932 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous Tramadol (1.5 mg.kg⁻¹)
Number of subjects: 30
Study 20863932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tramadol (1.5 mg.kg⁻¹)
Number of subjects: 30
Study 18175231 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse in fathers
Number of subjects: 94
Study 18175231 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in mothers
Number of subjects: 94
Study 18175231 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity in mothers
Number of subjects: 94
Study 18175231 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime mood disorder in participants
Number of subjects: 94
Study 18175231 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe depression in mothers
Number of subjects: 94
Study 16009149 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of peritoneal fluid at laparoscopic surgery
Number of subjects: 99
Study 12552190 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (n = 23), bolus of 2 x 10(6) kallikrein inactivator units (KIU), followed by an infusion of 5 x 10(5) KIU/h
Number of subjects: 69
Study 12552190 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon amino‐caproic acid (EACA) (n = 22), bolus of 150 mg/kg, followed by a 15 mg/kg/h infusion
Number of subjects: 69
Study 12552190 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (n = 24)
Number of subjects: 69
Study 10912891 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe Condition 1 (SC1)
Number of subjects: 19
Study 10912891 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe Condition 2 (SC2)
Number of subjects: 19
Study 10912891 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe Condition 3 (SC3)
Number of subjects: 19
Study 10912891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mislead group (SC1 and SC3 described as baseline measures)
Number of subjects: 19
Study 10912891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no investigator description)
Number of subjects: 19
Study 8696647 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-donated blood for pleurodesis (50 ml instillations, 120 ml for 1 patient)
Number of subjects: 14
Study 1802958 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine (HB Vax, MSD)
Number of subjects: 167
Study 1802958 — intervention group
Group type: COMPARATOR
Intervention: Recombinant hepatitis B vaccine (Engerix B, SK&F)
Number of subjects: 167
Study 6478342 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 62
Study 6478342 — intervention group
Group type: COMPARATOR
Intervention: Mozes Detector
Number of subjects: 62
Study 31487868 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical condition (diagnosed with food addiction)
Number of subjects: 962
Study 31487868 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-diagnosed condition (believed herself to be a food addict)
Number of subjects: 962
Study 31487868 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no reference to food addiction)
Number of subjects: 962
Study 29851819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual-task training combined with auditory motor synchronization training (CMDT + AMST), 3 sessions per week for 6 weeks
Number of subjects: 30
Study 29851819 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-motor dual-task training (CMDT), 3 sessions per week for 6 weeks
Number of subjects: 30
Study 26708615 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating vaginal pelvic floor training balls for 12 weeks
Number of subjects: 56
Study 26708615 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle exercises for 12 weeks
Number of subjects: 56
Study 25261340 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia-expectation condition
Number of subjects: 49
Study 25261340 — intervention group
Group type: COMPARATOR
Intervention: Control-expectation condition
Number of subjects: 49
Study 25261340 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (blue-colored hand disinfectant)
Number of subjects: 49
Study 25261340 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-MT boys
Number of subjects: 49
Study 25261340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MT boys
Number of subjects: 49
Study 22103778 — intervention group
Group type: COMPARATOR
Intervention: COXIB group (n = 30) received either 40 mg parecoxib iv or 120 mg etoricoxib orally 1 h before surgery.
Number of subjects: 89
Study 22103778 — intervention group
Group type: COMPARATOR
Intervention: STEROID group (n = 30) received 8 mg dexamethasone iv.
Number of subjects: 89
Study 22103778 — intervention group
Group type: EXPERIMENTAL
Intervention: Group COMBI (n = 29) received both COX-2 inhibitor and dexamethasone.
Number of subjects: 89
Study 20854949 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation at 6-month follow-up
Number of subjects: 2231
Study 17634165 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice flavonoid oil (LFO) at doses of 300 mg, 600 mg, and 1200 mg per day
Number of subjects: 5
Study 17634165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 16086879 — intervention group
Group type: EXPERIMENTAL
Intervention: NO regimen (LOHP plus NVB)
Number of subjects: 90
Study 16086879 — intervention group
Group type: COMPARATOR
Intervention: NP regimen (DDP plus NVB)
Number of subjects: 90
Study 12815799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt test in early stage IPD patients (n = 20)
Number of subjects: 35
Study 12815799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt test in advanced stage IPD patients (n = 15)
Number of subjects: 35
Study 12815799 — intervention group
Group type: COMPARATOR
Intervention: Tilt test in control group (n = 35)
Number of subjects: 35